Therapy of mantle cell lymphoma;Therapie des mantelzelllymphoms

Internist

Volumn 48, Issue 4, 2007, Pages 382-388

  Dreyling, M ^a   Unterhalt, M ^a   Weigert, O ^a   Hiddemann, W ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antibody treatment; Autologous stem cell transplantation; Chemotherapy; Mantle cell lymphoma; Review

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; IDARUBICIN; IMMUNOMODULATING AGENT; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, MANTLE-CELL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION;

EID: 34147220607     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-007-1803-3     Document Type: Article

References (34)

1. Brugger W, Hirsch J, Grunebach F et al. (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15: 1691-1698
2. Cohen BJ, Moskowitz C, Straus D et al. (2001) Cyclophosphamide/ fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42: 1015-1022
3. Dreger P, Martin S, Kuse R et al. (2000) The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 1: 87-94
4. Dreyling M, Lenz G, Hoster E et al. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma - results of a prospective randomized trial of the European MCL Network. Blood 105: 2677-2684
5. Fisher RI, Bernstein SH, Kahl BS et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874
6. Forstpointner R, Dreyling M, Repp R et al. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low Grade Lymphoma Study Group Blood 104: 1064-1071
7. Forstpointner R, Unterhalt M, Dreyling et al. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (RFCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003-4008
8. Ghielmini M, Schmitz SF, Cogliatti S et al. (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23: 705-711
9. Gianni AM, Magni M, Martelli M et al. (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102: 749-755
10. Gopal AK, Rajendran JG, Petersdorf SH et al. (2002) High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99: 3158-3162
11. Herold M, Pasold R, Srock S et al. (2004) Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood (Suppl 1) 104: 584a
12. Hiddemann W, Unterhalt M, Herrmann R et al. (1998) Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 16: 1922-1930
13. Hiddemann W, Dreyling MH, Tiemann M et al. (1999) Mantle cell lymphomas. Haematologica 84: 93-95
14. Howard OM, Gribben JG, Neuberg DS et al. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20: 1288-1294
15. Jaffe ES, Harris NL, Stein H et al. (Eds) (2001) World Health Organisation classification of tumours: Tumours of the haemopoitic and lymphoid tissues. IARC Press, Lyon
16. Kaufmann H, Raderer M, Wohrer S et al. (2004) Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104: 2269-2271
17. Khouri IF, Lee MS, Saliba RM et al. (2003) Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21: 4407-4412
18. Lefrere F, Delmer A, Levy V et al. (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89: 1275-1276
19. Leitch HA, Gascoyne RD, Chhanabhai M et al. (2003) Limited-stage mantle-cell lymphoma. Ann Oncol 14: 1555-1561
20. Lenz G, Dreyling M, Hoster E et al. (2005) Immunochemotherapy with rituximab and CHOP significantly improves response and time to treatment failure but not long-term outcome in patients with previously untreated mantle cell lymphoma - results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984-1992
21. Meusers P, Engelhard M, Bartels H et al. (1989) Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 7: 365-380
22. Meusers P, Hense J, Brittinger G (1997) Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia (Suppl 2) 11: S60-S64
23. Nickenig C, Dreyling M, Hoster E et al. (2006) Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 107: 1014-1022
24. Oki Y, Pro B, Delpassand E et al. (2004) A phase II study of 90Yttrium-ibritumomab (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 104: 720a [abstract]
25. Robinson SP, Goldstone AH, Mackinnon S et al. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100: 4310-4316
26. Romaguera JE, Fayad L, Rodriguez MA et al. (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23: 7013-7023
27. Stewart DA, Vose JM, Weisenburger DD et al. (1995) The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6: 263-266
28. Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. (1995) Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13: 2819-2826
29. Unterhalt M, Herrmann R, Tiemann M et al. (1996) Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group. Leukemia 10: 836-843
30. Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al. (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120: 793-800
31. 90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLSG. Annual Meeting of the American Society of Oncology, Atlanta. J Clin Oncol 24: No 18S: 7502
32. Weigert O, Pastore A, Rieken M et al. (2006) Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia (in press)
33. Witzig TE, Geyer SM, Ghobrial I et al. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-5356
34. Zucca E, Roggero E, Pinotti G et al. (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol 6: 257-262